Integrated data from the phase 2 ONSET-1 and phase 3 ONSET-2 clinical trials showed that OC-01 nasal spray effectively improves endogenous basal tear production in a heterogeneous dry eye disease population.
The results of this analysis were presented in a poster session at the American Academy of Ophthalmology meeting by John Sheppard, MD.
“Tear film homeostasis is controlled by the parasympathetic nervous system. A loss of parasympathetic stimuli results in chronic reduction of tear secretion and morphologic destruction of the lacrimal gland,” Sheppard said.
OC-01 (varenicline